Article info
PDFOriginal research
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines
- Correspondence to Dr Zhang Zhang, Department of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; zhangzhang714{at}163.com
Citation
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines
Publication history
- Received September 18, 2019
- Revised October 21, 2019
- Accepted October 22, 2019
- First published November 15, 2019.
Online issue publication
August 11, 2020
Article Versions
- Previous version (20 April 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.